HIV-1 matrix mutations that alter gag membrane binding modulate mature core formation and post-entry events.


Journal

Virology
ISSN: 1096-0341
Titre abrégé: Virology
Pays: United States
ID NLM: 0110674

Informations de publication

Date de publication:
06 2019
Historique:
received: 29 03 2019
revised: 24 04 2019
accepted: 25 04 2019
pubmed: 6 5 2019
medline: 8 7 2020
entrez: 6 5 2019
Statut: ppublish

Résumé

The matrix (MA) domain of HIV-1 Gag directs membrane binding of the Gag precursor polyprotein during the late events of virus replication. However, the effects of alteration in Gag membrane binding early post-infection are not well understood. To investigate impacts of MA mutations that alter Gag membrane binding on the phenotypes of newly produced virus particles, we extensively characterized two MA mutants by virological, biochemical, and morphological approaches. The V6R mutation, which decreases Gag membrane binding, modified Gag processing and core morphogenesis and impaired core uncoating, reverse transcription, and viral DNA integration. On the other hand, the L20K mutation, which increases Gag membrane binding, primarily decreased integrated DNA levels without affecting the viral components and morphology. These data suggest that HIV-1 MA plays roles in functional core formation and the following post-entry steps of the virus replication cycle. (140/150 words).

Identifiants

pubmed: 31055063
pii: S0042-6822(19)30113-8
doi: 10.1016/j.virol.2019.04.013
pii:
doi:

Substances chimiques

Protein Precursors 0
Viral Matrix Proteins 0
gag Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

97-107

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Yuta Hikichi (Y)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan; The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. Electronic address: yhikichi0@niid.go.jp.

Eri Takeda (E)

Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, 565-0871, Japan. Electronic address: etakeda@biken.osaka-u.ac.jp.

Masayuki Fujino (M)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan. Electronic address: fmasa@nih.go.jp.

Emi Nakayama (E)

Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, 565-0871, Japan. Electronic address: emien@biken.osaka-u.ac.jp.

Tetsuro Matano (T)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan; The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. Electronic address: tmatano@nih.go.jp.

Tsutomu Murakami (T)

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan. Electronic address: tmura@nih.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH